The FDA is about to decide whether it will approve the first new drug for the treatment of Alzheimer’s in almost two decades. Jeff Borghoff fervently hopes the answer is yes. He has early onset Alzheimer’s and has been taking the drug for years. In this video interview, he tells his story and makes the case for why the drug aducanumab deserves approval. (Editor’s note: Jeff does want to clarify one statement he made during the interview. The spinal tap he underwent was to detect the tau protein, which is another biomarker of Alzheimer’s.)
Read my my full article about Jeff Borghoff and the impending FDA decision here.
Learn more about Jeff and his advocacy on issues affecting people with cognitive impairment by visiting his website here.